华熙生物裁员“止血”,“玻尿酸女王”豪赌减肥新赛道

雷达Finance
Sep 17, 2025

雷达财经出品 文|丁禹 编|孟帅身为“玻尿酸三剑客”之一的华熙生物,如今正陷入一场深度的结构性调整与战略重塑之中。在经历持续裁员、品牌收缩、业绩承压等多重阵痛后,这个玻尿酸巨头做出了一个具有转折意义的战略抉择。近日,华熙生物通过旗下子公司斥资1.38亿港元战略投资圣诺医药,成为前者的第二大股东,剑指小核酸药物赛道,发力定向减脂领域,以期开辟第二增长曲线。而这一战略布局的背后,是华熙生物所面临的严峻...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10